Paladin Labs Inc. (CC:PLB) and Somaxon Pharmaceuticals, Inc. (SOMX) Announce Filing of New Drug Submission for SilenorĀ®  
2/23/2012 6:07:32 AM

MONTREAL & SAN DIEGO--(BUSINESS WIRE)--Paladin Labs Inc. (TSX:PLB) and Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced that Paladin has filed a New Drug Submission (NDS) that has been accepted for review by Health Canada for SilenorĀ® (doxepin) for the treatment and symptomatic relief of insomnia.